Cyclin-dependent kinases (Cdk) and their associated pathways represent some of the most attractive targets for the development of anticancer
therapeutics. Based on antitumor activity in animal models, a variety of Cdk inhibitors are undergoing clinical evaluation either as a single agent or in combination with other approved drugs. In our anticancer
drug discovery program, a novel series of
flavones have been synthesized for evaluation against the activity of Cdk4-D1. This
enzyme catalyzes the phosphorylation of
retinoblastoma protein, thus inhibiting its function. We have identified a series of potent Cdk4-D1 inhibitors with IC(50) below 250 nmol/L. In this report, we have described the properties of one of the best compound,
P276-00 of the
flavone's series.
P276-00 shows 40-fold selectivity toward Cdk4-D1, compared with Cdk2-E. The specificity toward 14 other related and unrelated
kinases was also determined.
P276-00 was found to be more selective with IC(50)s <100 nmol/L for Cdk4-D1, Cdk1-B, and Cdk9-T1, as compared with other Cdks, and less selective for non-Cdk
kinases. It showed potent antiproliferative effects against various human
cancer cell lines, with an IC(50) ranging from 300 to 800 nmol/L and was further compared for its antiproliferative activity against
cancer and normal fibroblast cell lines.
P276-00 was found to be highly selective for
cancer cells as compared with normal fibroblast cells. To delineate its mechanism of action, the effect of
P276-00 on
cell cycle proteins was studied in human
breast cancer cell line (MCF-7) and human
non-small cell lung carcinoma (H-460). A significant down-regulation of
cyclin D1 and Cdk4 and a decrease in Cdk4-specific pRb Ser(780) phosphorylation was observed.
P276-00 produced potent inhibition of Cdk4-D1 activity that was found to be competitive with
ATP and not with
retinoblastoma protein. The compound also induced apoptosis in human promyelocytic
leukemia (HL-60) cells, as evidenced by the induction of
caspase-3 and
DNA ladder studies. These data suggest that
P276-00 has the potential to be developed as an anti-Cdk chemotherapeutic agent.